Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial.
作者信息
Popat Rakesh, Warcel Dana, O'Nions Jenny, Cowley Anna, Smith Sasha, Tucker William R, Yong Kwee, Esposti Simona Degli
机构信息
National Institute for Health Research Clinical Research Facility, University College London Hospitals NHS Foundation Trust
National Institute for Health Research Clinical Research Facility, University College London Hospitals NHS Foundation Trust.
出版信息
Haematologica. 2020 May;105(5):e261-e263. doi: 10.3324/haematol.2019.235937. Epub 2020 Feb 27.
Abstract
摘要
相似文献
1
Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial.复发多发性骨髓瘤患者接受贝兰他单抗马福多汀（GSK2857916）单药治疗后长期随访的反应及角膜事件特征：首例人体临床试验的病例系列
Haematologica. 2020 May;105(5):e261-e263. doi: 10.3324/haematol.2019.235937. Epub 2020 Feb 27.
2
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.贝兰他单抗马妥昔单抗治疗复发或难治性多发性骨髓瘤（DREAMM-2）：一项双臂、随机、开放标签、2 期研究。
Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.
3
Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.贝兰他单抗马妥昔单抗在复发或难治性多发性骨髓瘤中的治疗应用。
Future Oncol. 2020 Dec;16(34):2783-2798. doi: 10.2217/fon-2020-0521. Epub 2020 Sep 2.
4
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.EMA 审查贝兰他单抗mafodotin（Blenrep）治疗成人复发/难治性多发性骨髓瘤。
Oncologist. 2021 Jan;26(1):70-76. doi: 10.1002/onco.13592. Epub 2020 Nov 23.
5
Belantamab Mafodotin to Treat Multiple Myeloma: A Comprehensive Review of Disease, Drug Efficacy and Side Effects.贝兰他单抗马妥昔单抗治疗多发性骨髓瘤：疾病、药物疗效和副作用的全面综述。
Curr Oncol. 2021 Jan 21;28(1):640-660. doi: 10.3390/curroncol28010063.
6
Belantamab mafodotin for the treatment of multiple myeloma.贝兰他单抗马妥昔单抗用于多发性骨髓瘤的治疗。
Drugs Today (Barc). 2021 Nov;57(11):653-663. doi: 10.1358/dot.2021.57.11.3319146.
7
Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.在复发/难治性多发性骨髓瘤患者中，针对贝兰他单抗mafodotin 的治疗剂量选择进行暴露-反应分析。
Clin Pharmacol Ther. 2021 Nov;110(5):1282-1292. doi: 10.1002/cpt.2409. Epub 2021 Oct 4.
8
Belantamab Mafodotin: First Approval.贝兰他单抗mafodotin：首次批准。
Drugs. 2020 Oct;80(15):1607-1613. doi: 10.1007/s40265-020-01404-x.
9
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.贝兰他单抗马妥昔单抗联合新型药物治疗复发/难治性多发性骨髓瘤：DREAMM-5 研究设计。
Future Oncol. 2021 Jun;17(16):1987-2003. doi: 10.2217/fon-2020-1269. Epub 2021 Mar 8.
10
"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience.硼替佐米、卡非佐米和来那度胺联合方案治疗多发性骨髓瘤患者的真实世界研究：梅奥诊所的经验
Blood Cancer J. 2021 Dec 7;11(12):196. doi: 10.1038/s41408-021-00592-3.
引用本文的文献
1
Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies.与癌症抗体药物偶联物相关的眼部不良事件：证据和管理策略。
Oncologist. 2024 Nov 4;29(11):e1435-e1451. doi: 10.1093/oncolo/oyae177.
2
Incidence and Mitigation of Corneal Pseudomicrocysts Induced by Antibody-Drug Conjugates (ADCs).抗体药物偶联物（ADCs）诱导的角膜假性微囊肿的发生率及缓解情况
Curr Ophthalmol Rep. 2024 Jun;12(2):13-22. doi: 10.1007/s40135-024-00322-5. Epub 2024 Mar 24.
3
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma.泪液中可溶性 B 细胞成熟抗原作为多发性骨髓瘤角膜病的潜在生物标志物和介质。
Haematologica. 2024 Nov 1;109(11):3670-3680. doi: 10.3324/haematol.2024.285205.
4
Ocular Surface Side Effects of Novel Anticancer Drugs.新型抗癌药物的眼表副作用。
Cancers (Basel). 2024 Jan 13;16(2):344. doi: 10.3390/cancers16020344.
5
Corneal epithelial changes in a patient treated with belantamab mafodotin.接受贝兰他单抗莫福汀治疗患者的角膜上皮变化
Taiwan J Ophthalmol. 2023 Aug 11;13(3):380-383. doi: 10.4103/tjo.TJO-D-22-00171. eCollection 2023 Jul-Sep.
6
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.替西木单抗 Ravtansine 治疗晚期实体瘤患者的安全性、药代动力学和抗肿瘤活性的 I 期研究：采用不同剂量方案
Cancer Res Commun. 2023 Aug 28;3(8):1662-1671. doi: 10.1158/2767-9764.CRC-23-0284. eCollection 2023 Aug.
7
Adverse events of antibody-drug conjugates on the ocular surface in cancer therapy.抗体药物偶联物在癌症治疗中对眼表面的不良反应。
Clin Transl Oncol. 2023 Nov;25(11):3086-3100. doi: 10.1007/s12094-023-03261-y. Epub 2023 Jul 15.
8
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences.贝兰他单抗莫福汀：从临床试验数据到真实生活经验
Cancers (Basel). 2023 May 27;15(11):2948. doi: 10.3390/cancers15112948.
9
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.基于法国命名 ATU 数据的真实世界研究：IFM 2020-04 研究，评估贝兰他单抗mafodotin（GSK2857916）在复发或难治性多发性骨髓瘤中的疗效和安全性。
Haematologica. 2023 Oct 1;108(10):2774-2782. doi: 10.3324/haematol.2022.281772.
10
[Belantamab mafodotin-associated keratopathy-A common and treatment-affecting side effect].[贝利妥昔单抗相关角膜病变——一种常见且影响治疗的副作用]
Ophthalmologie. 2023 Apr;120(4):418-422. doi: 10.1007/s00347-022-01660-0. Epub 2022 May 31.
本文引用的文献
1
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.贝兰他单抗马妥昔单抗治疗复发或难治性多发性骨髓瘤（DREAMM-2）：一项双臂、随机、开放标签、2 期研究。
Lancet Oncol. 2020 Feb;21(2):207-221. doi: 10.1016/S1470-2045(19)30788-0. Epub 2019 Dec 16.
2
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study.抗体药物偶联物 GSK2857916 治疗复发/难治性多发性骨髓瘤：来自 I 期剂量扩展研究的安全性和疗效更新。
Blood Cancer J. 2019 Mar 20;9(4):37. doi: 10.1038/s41408-019-0196-6.
3
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.以复发或难治性多发性骨髓瘤中的 B 细胞成熟抗原为靶点的 GSK2857916 抗体药物偶联物（BMA117159）：一项剂量递增和扩展的 1 期试验。
Lancet Oncol. 2018 Dec;19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X. Epub 2018 Nov 12.
4
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.靶向多发性骨髓瘤中的 B 细胞成熟抗原（BCMA）：基于 BCMA 的免疫疗法的潜在用途。
Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. eCollection 2018.
5
Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates.调控巨胞饮介导的内化作用可降低抗体药物偶联物的眼部毒性。
Cancer Res. 2018 Apr 15;78(8):2115-2126. doi: 10.1158/0008-5472.CAN-17-3202. Epub 2018 Jan 30.
6
Update in Current Diagnostics and Therapeutics of Dry Eye Disease.干眼疾病当前诊断与治疗的进展
Ophthalmology. 2017 Nov;124(11S):S27-S33. doi: 10.1016/j.ophtha.2017.07.022.
7
Multiple myeloma.多发性骨髓瘤。
Nat Rev Dis Primers. 2017 Jul 20;3:17046. doi: 10.1038/nrdp.2017.46.
8
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma.ABT-414 联合放疗和替莫唑胺治疗新诊断胶质母细胞瘤的疗效和安全性结果。
Neuro Oncol. 2017 Jul 1;19(7):965-975. doi: 10.1093/neuonc/now257.
9
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.抗体、药物和连接子对抗体药物偶联物临床前和临床毒性的影响。
MAbs. 2016 May-Jun;8(4):659-71. doi: 10.1080/19420862.2016.1156829. Epub 2016 Apr 5.
10
Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.人类临床试验中与抗体药物偶联物相关的眼部不良事件。
J Ocul Pharmacol Ther. 2015 Dec;31(10):589-604. doi: 10.1089/jop.2015.0064. Epub 2015 Nov 5.
Zotero 插件